National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 78320-78321 [2024-21860]
Download as PDF
<![CDATA[
78320
Federal Register / Vol. 89, No. 186 / Wednesday, September 25, 2024 / Notices
Review Group; Advancing Therapeutics—B
Study Section.
Date: October 24–25, 2024.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Lystranne Alysia Maynard
Smith, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–402–4809,
lystranne.maynard-smith@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 19, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–21898 Filed 9–24–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meetings
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Advancing Genomic Medicine
Research.
Date: October 29, 2024.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Suite 3100, Bethesda, MD
20892 (Virtual).
Contact Person: Lori Bonnycastle, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Suite 3100, Bethesda, MD 20892, 301–594–
9206, lbonnyca@mail.nih.gov.
VerDate Sep<11>2014
17:28 Sep 24, 2024
Jkt 262001
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Regional Genomic Medicine eConsult
Services.
Date: November 13, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Suite 3100, Bethesda, MD
20892 (Virtual).
Contact Person: Sarah J. Wheelan, MD,
Ph.D., Scientific Review Officer, National
Human Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Room 3180, Bethesda, MD 20892, (301) 402–
8823, wheelansj@nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Training Grant.
Date: November 14, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Suite 3100, Bethesda, MD
20892 (Virtual).
Contact Person: Rudy O. Pozzatti, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Suite 3100, Bethesda, MD 20892, (301) 402–
0838, pozzattr@mail.nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Computational Genomics and Data
Science Education.
Date: November 18, 2024.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Suite 3100, Bethesda, MD
20892 (Virtual).
Contact Person: Sarah J. Wheelan, MD,
Ph.D., Scientific Review Officer, National
Human Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Room 3180, Bethesda, MD 20892, (301) 402–
8823, wheelansj@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: September 19, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–21900 Filed 9–24–24; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; URGenT: Translational
Efforts to Advance Gene-based Therapies for
Ultra-Rare Neurological and Neuromuscular
Disorders.
Date: October 17, 2024.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Mirela Milescu, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH/DHHS, NSC, 6001 Executive
Boulevard, Rockville, MD 20852,
mirela.milescu@nih.gov, 301–496–5720.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS).
Dated: September 19, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–21901 Filed 9–24–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
BILLING CODE 4140–01–P
PO 00000
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
Frm 00042
Fmt 4703
Sfmt 4703
E:\FR\FM\25SEN1.SGM
25SEN1
Federal Register / Vol. 89, No. 186 / Wednesday, September 25, 2024 / Notices
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: November 4, 2024.
Time: 10:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F21B,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Maryam Feili-Hariri,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F21B,
Rockville, MD 20892, 240–669–5026,
haririmf@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 19, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–21860 Filed 9–24–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
ddrumheller on DSK120RN23PROD with NOTICES1
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
VerDate Sep<11>2014
17:28 Sep 24, 2024
Jkt 262001
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Device
Based Treatments for Substance Use
Disorders.
Date: October 30, 2024.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Preethy Nayar, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 443–4577, nayarp2@
csr.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Analytical Service Center for Medications
Development Program.
Date: October 30, 2024.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Trinh T. Tran, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–5843, trinh.tran@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Developing Regulated Therapeutic and
Diagnostic Solutions for Patients Affected by
Opioid and/or Stimulants Use Disorders.
Date: November 7–8, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sudhirkumar U.
Yanpallewar, M.D., Scientific Review Officer,
Scientific Review Branch, Office of
Extramural Policy, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 443–
4577, sudhirkumar.yanpallewar@nih.gov.
Name of Committee: National Institute on
Drug Abuse Initial Review Group;
Medication Development Research Study
Section.
Date: November 13, 2024.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
78321
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Preethy Nayar, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, 301–443–4577, nayarp2@
csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: September 19, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–21859 Filed 9–24–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: October 18, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 903 South 4th Street, RML 31/3118,
Hamilton, MT 59840 (Video Assisted
Meeting).
Contact Person: Kristin L. McNally, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 903
South 4th Street, RML 31/3118, Hamilton,
MT 59840, mcnallyk@niaid.nih.gov.
E:\FR\FM\25SEN1.SGM
25SEN1
]]>Agencies
[Federal Register Volume 89, Number 186 (Wednesday, September 25, 2024)]
[Notices]
[Pages 78320-78321]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21860]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
[[Page 78321]]
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical Trial Not Allowed).
Date: November 4, 2024.
Time: 10:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F21B,
Rockville, MD 20892 (Video Assisted Meeting).
Contact Person: Maryam Feili-Hariri, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F21B,
Rockville, MD 20892, 240-669-5026, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: September 19, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-21860 Filed 9-24-24; 8:45 am]
BILLING CODE 4140-01-P
